Search research articles
Contact Us
Filters
Showing results (461-470 of 962) with videos related to
Page
of 97
Sort By:
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
The New England Journal of Medicine
|
September 8, 2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Gilles Montalescot, Harvey D White, Richard Gallo, et al.
European Heart Journal
|
September 2, 2009
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
Mark J Alberts, Deepak L Bhatt, Jean-Louis Mas, et al.
The American Journal of Cardiology
|
February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
JACC. Cardiovascular Interventions
|
November 21, 2009
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
Gilles Montalescot, Richard Gallo, Harvey D White, et al.
Journal of Clinical Medicine
|
December 22, 2019
Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry
Emmanuelle Vidal-Petiot, Nicola Greenlaw, Paul R Kalra, et al.
International Journal of Cardiology
|
October 15, 2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Alon Eisen, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology
|
May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy
Benjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
Journal of the American Heart Association
|
April 16, 2017
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding
Daniel Lindholm, Emil Hagström, Stefan K James, et al.
European Heart Journal
|
March 4, 2014
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Dharam J Kumbhani, Ph Gabriel Steg, Christopher P Cannon, et al.
Page
of 97
Search research articles
Search
Showing results (461-470 of 962) with videos related to
Sort By:
Page
of 97
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
The New England Journal of Medicine
|
September 8, 2006
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
Gilles Montalescot, Harvey D White, Richard Gallo, et al.
European Heart Journal
|
September 2, 2009
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
Mark J Alberts, Deepak L Bhatt, Jean-Louis Mas, et al.
The American Journal of Cardiology
|
February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
JACC. Cardiovascular Interventions
|
November 21, 2009
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
Gilles Montalescot, Richard Gallo, Harvey D White, et al.
Journal of Clinical Medicine
|
December 22, 2019
Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry
Emmanuelle Vidal-Petiot, Nicola Greenlaw, Paul R Kalra, et al.
International Journal of Cardiology
|
October 15, 2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Alon Eisen, Robert A Harrington, Gregg W Stone, et al.
Journal of the American College of Cardiology
|
May 7, 2011
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy
Benjamin M Scirica, Christopher P Cannon, Håkan Emanuelsson, et al.
Journal of the American Heart Association
|
April 16, 2017
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding
Daniel Lindholm, Emil Hagström, Stefan K James, et al.
European Heart Journal
|
March 4, 2014
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Dharam J Kumbhani, Ph Gabriel Steg, Christopher P Cannon, et al.
Page
of 97